Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Thomas J. Prior"'
Autor:
Thomas J. Prior
Publikováno v:
Statistical Methods in Medical Research. 29:3525-3532
Clinical trials in oncology often involve the statistical analysis of time-to-event data such as progression-free survival or overall survival to determine the benefit of a treatment or therapy. The log-rank test is commonly used to compare time-to-e
Autor:
Jesus G. Berdeja, BW Hilderq, Thomas J. Prior, Monique C. Minnema, Luciano J. Costa, Paula Rodriguez-Otero, Aparna Krishnan, Jenna D. Goldberg, Ajai Chari, Albert Oriol, Jeffery S. Russell, Raluca Verona, E Askari, S Girgisq, M.V. Mateos, Nwv Donk
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S215-S216 (2021)
Objectives Patients with MM continue to relapse on current therapies, stressing the need for new immunotherapy targets. GPRC5D is an orphan receptor that is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 an
Autor:
Thomas J. Prior, Luciano J. Costa, Monique C. Minnema, Niels W.C.J. van de Donk, Maria-Victoria Mateos, Jesus G. Berdeja, Ajai Chari, Jeffery S. Russell, Raluca Verona, Suzette Girgis, Elham Askari, Paula Rodriguez-Otero, Amrita Krishnan, A. Oriol, Brandi Hilder, Jenna D. Goldberg
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S16-S17
Background As patients (pts) with MM continue to relapse, new immunotherapy targets are needed. GPRC5D is an orphan receptor that is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that binds to the
Autor:
Thomas J. Prior, Donna E. Reece, Paula Rodriguez-Otero, Amrita Krishnan, Maria-Victoria Mateos, Bhagirathbhai Dholaria, Parameswaran Hari, Daniel Morillo Giles, Niels W.C.J. van de Donk, Jesús F. San-Miguel, Mark Wade, Ajai Chari, Hartmut Goldschmidt, Alfred L. Garfall, Elham Askari, K. Martin Kortuem, Jenna D. Goldberg, Saad Z. Usmani, Cesar Rodriguez, Raluca Verona, Brendan M. Weiss, Nizar J. Bahlis, Albert Oriol, Shun Xin Wang Lin, Thomas Martin
Publikováno v:
Blood. 138:161-161
Introduction: Novel agents are needed for multiple myeloma (MM), which remains incurable with most patients (pts) relapsing or becoming refractory to standard therapies. Talquetamab (Tal) is a bispecific antibody that binds to G protein-coupled recep
Autor:
Ralph Wäsch, Jesús F. San-Miguel, Hartmut Goldschmidt, Laura Rosiñol, Niels W.C.J. van de Donk, Donna E. Reece, Cesar Rodriguez, Ajai Chari, Thomas J. Prior, Maria-Victoria Mateos, Anna Sureda, Shun Xin Wang Lin, Jenna D. Goldberg, Katja Weisel, Paula Rodriguez-Otero, Amrita Krishnan, Parameswaran Hari, Mark Wade, Albert Oriol, Raluca Verona, Bhagirathbhai Dholaria, Thomas Martin, Elham Askari, Daniel Morillo Giles, Brendan M. Weiss
Publikováno v:
Blood. 138:1647-1647
Introduction: Teclistamab (Tec) is a B-cell maturation antigen × CD3 T-cell redirecting bispecific antibody. In the phase 1 MajesTEC-1 trial in patients (pts) with heavily pretreated relapsed/refractory multiple myeloma (RRMM), Tec monotherapy was w
Autor:
Brandi Hilder, Paula Rodriguez, Albert Oriol, Jesus G. Berdeja, Maria-Victoria Mateos, Suzette Girgis, Jeffery S. Russell, Raluca Verona, Thomas J. Prior, Monique C. Minnema, Ajai Chari, Niels W.C.J. van de Donk, Elham Askari, Amrita Krishnan, Jenna D. Goldberg
Publikováno v:
Blood. 136:40-41
Despite improved outcomes with current MM treatments, most patients (pts) will develop refractory disease, highlighting the need for novel treatments. GPRC5D is an orphan receptor whose transcript is highly expressed in primary MM cells but has gener
Autor:
Thomas J. Prior, Monique C. Minnema, Ajai Chari, Suzette Girgis, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Amrita Krishnan, Maria-Victoria Mateos, Jesus G. Berdeja, Luciano J. Costa, Elham Askari, Jenna D. Goldberg, Jeffery S. Russell, Raluca Verona, Brandi Hilder, Albert Oriol
Publikováno v:
Journal of Clinical Oncology. 39:8008-8008
8008 Background: New immunotherapy targets in MM are needed as patients (pts) continue to relapse. The orphan receptor GPRC5D is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that redirects T cell
Autor:
Daniel A. Sussman, David S. Weinberg, Kelly Raybold, Bryson W. Katona, Jean-Christophe Saurin, Carol A. Burke, Edward F. Attiyeh, Evelien Dekker, Hong Xie, Eduardo Vilar-Sanchez, Thomas J. Prior, Gary V. Borzillo, Douglas L. Riegert-Johnson, Xavier Llor, Peter P. Stanich, Jeffrey R. Infante, Niloy Jewel Samadder, Philippe Grandval, Kurtis E. Bachman, William M. Grady, Marcia Cruz Correa, Devanand Joseph, Michael Smith
Publikováno v:
Cancer Research. 80:CT236-CT236
Background: Familial adenomatous polyposis (FAP) is the most common hereditary polyposis syndrome. It is an autosomal dominant inherited disorder characterized by the early onset of hundreds to thousands of adenomatous polyps throughout the colon. If
Publikováno v:
The Patient: Patient-Centered Outcomes Research. 5:279-294
While the application of conjoint analysis and discrete-choice experiments in health are now widely accepted, a healthy debate exists around competing approaches to experimental design. There remains, however, a paucity of experimental evidence compa
Autor:
John F.P. Bridges, A. Brett Hauber, Juan Marcos Gonzalez, Deborah A. Marshall, Charles E. Cunningham, Maarten Joost IJzerman, Catharina G.M. Groothuis-Oudshoorn, Thomas J. Prior
Publikováno v:
Value in health, 19(4), 300-315. Elsevier
Conjoint analysis is a stated-preference survey method that can be used to elicit responses that reveal preferences, priorities, and the relative importance of individual features associated with health care interventions or services. Conjoint analys